Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Unknown 1Terminated 1Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1

Interventions

anlotinib 5Cisplatin 5Carboplatin 5Immune Checkpoint Inhibitors 4tislelizumab 3sintilimab 3lenvatinib 3Oxaliplatin 3Fluorouracil 3Capecitabine 3Bevacizumab 3venetoclax 2Rosuvastatin Calcium 2Prednisone 2Megestrol Acetate 2Leucovorin 2Gemcitabine 2Drug Therapy 2Dexmedetomidine 2Dexamethasone 2Aspirin 2zanubrutinib 1xiaojin wan 1trastuzumab deruxtecan 1trametinib 1toripalimab 1tocilizumab 1testosterone 17 beta-cypionate 1tenofovir alafenamide 1telitacicept 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Not yet recruiting × flumatinib × Clear all
NCT05367765 2022-05-10

A Real World Study of the Efficacy and Safety of Flumatinib Versus Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Phase 4 Not yet recruiting
2,400 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

Data powered by HemOnc (CC BY 4.0) Colophon âš¡